Aster DM Quality Care shares soar 8% as Q2 PAT grows 34% YoY, patient volume surges 12% to 2.2 million

The stock gained as the company reported a 34% year-on-year (YoY) surge in its consolidated normalised profit after tax (PAT) to ₹281 crore in the July-September quarter of the 2026-27 financial year (Q2 FY27), compared with ₹210 crore it logged in the corresponding period of the preceding fiscal year.

In July 2026, Aster DM Healthcare completed its merger with Quality Care India and was renamed Aster DM Quality Care. Thus, its normalised PAT (post NCI) for Q2 FY27 excludes exceptional expenses related to the merger & share of loss from equity-accounted investees, it said in an investor presentation dated November 6.

Its revenue from operations jumped 19% YoY to ₹2,829 crore during the quarter under review, as against ₹2,156 crore in the second quarter of the 2025-26 fiscal year (Q2 FY26).

Its topline growth was supported by higher volumes, greater clinical complexity and a favourable payor mix.

During the quarter, the patient volume grew 12% YoY to 2.2 million, led by Neurosciences, Oncology, Orthopedics and Gastroenterology.

Aster DM Quality Care witnessed encouraging growth across complex clinical procedures, with robotic surgeries, kidney transplants and joint replacements growing by approximately 39%, 31% and 29%, respectively. This was driven by patient volume growth in key specialties and growth in medical value travel (MVT) patient flows.

Its MVT volume soared 31% YoY, and revenue for the same advanced 36% YoY in Q2 FY27, bolstered by Maldives and Gulf Cooperation Council (GCC) markets, with rising contribution from West Africa and other Middle East and North Africa (MENA) countries. The volumes grew despite a challenging external environment.

Its emerging hospital portfolio, including Kasargod and Nagarcoil, recorded 61% YoY growth.

“Looking ahead, we remain focused on expanding our healthcare network, including progressing the Aster Trivandrum project towards commissioning, while continuing to invest in clinical talent, advanced infrastructure and technology. Our priority remains delivering better patient outcomes, strengthening operational excellence and creating sustainable long-term value for all stakeholders,” said Dr. Azad Moopen, Executive Chairman of Aster DM Quality Care.

Varun Khanna, Managing Director & Group CEO, said that going forward the firm’s focus will be on expanding its CONGO and other high-end specialties, augmenting capacity across geographies, strengthening clinical talent and improving access to quality healthcare, while unlocking the full potential of its combined network.

Aster DM Quality Care’s CONGO mix spans Cardiology, Oncology, Neurology, Gastroenterology and Orthopaedics.

Aster DM Quality Care share performance

At around 2:53 PM, the stock was trading 5.98% higher at ₹755.80 per equity share. The scrip has jumped 11% in the past week and more than 10% over the month. On a year-to-date (YTD) basis, it has rallied 25%.

While the shares hit a 52-week high of ₹891.30 per unit on August 10, 2026, they touched a year’s low of ₹519.10 apiece on February 4, 2026.

Aster DM Quality Care has a total market capitalisation of ₹65,924.59 crore as of November 8, 2026, according to data on the NSE.